PAVmed Inc.: Q3 FY2026 earnings call
What management said about Q3 FY2026, from the documents filed with the SEC on 13 November 2026: press release. Guidance figures: 1 kept. The quarter’s numbers.
Key takeaways
- Non-GAAP adjusted loss per share: Non-GAAP adjusted net loss was about $1.2 million, or $(0.19) per share, against $(0.27) in 2Q26 and $(0.62) in 3Q25. The measure excludes stock-based and other non-cash items. Source
- Medicare payments began in October: Lucid began receiving Medicare payments in October. Claims for its Texas laboratory go to Novitas, the MAC, and are paid at the established Clinical Laboratory Fee Schedule rate. Source
- Test volume and revenue in 3Q26: The company performed 2,871 EsoGuard tests and recognized $1.2 million of revenue in 3Q26, against 2,770 tests and $1.5 million of revenue in 2Q26. Source
- OSU-The James enrollment nearly doubled: Monthly patient enrollment at OSU-The James rose through the quarter, nearly doubling from July to September, as the commercial phase of the engagement accelerated. Source
- Implantable monitor design freeze reached: Veris achieved design freeze for the implantable physiological monitor and began a 90-day GLP animal study in October. Source
- Cash balance rose to $8.9 million: Cash and equivalents, including restricted cash, were $8.9 million at September 30, 2026, up from $3.8 million at June 30, 2026. Restricted cash was $5.3 million. Source
- Lucid largest common shareholder: Management said PAVmed is Lucid's largest common shareholder and stands to benefit directly from Lucid's near-term revenue following Medicare reimbursement. Source
“Lucid securing Medicare reimbursement for EsoGuard is a critical and transformational milestone.”
Lishan Aklog, M.D., Chairman and Chief Executive Officer
Guidance
| Area | Period | Figure | Against last quarter |
|---|---|---|---|
| FDA submission timing Source | Implantable physiological monitor, FDA 510(k) submission | early 2027 | Kept |
What changed from last quarter
- New: Lucid began receiving Medicare payments for EsoGuard in October. The prior release described a laboratory benefit manager coverage policy instead. Source
Results and loss measures
- Non-GAAP adjusted loss per share: Non-GAAP adjusted net loss was about $1.2 million, or $(0.19) per share, against $(0.27) in 2Q26 and $(0.62) in 3Q25. The measure excludes stock-based and other non-cash items. Source
- Operating expenses fell from 2Q26: Operating expenses were $6.8 million, compared with $7.1 million in 2Q26 and $4.8 million in 3Q25. The figure includes $1.0 million of stock-based compensation. Source
- Net loss attributable to common stockholders: The reconciliation table shows a net loss attributable to common stockholders of $11,752 thousand for 3Q26, against $5,479 thousand in 2Q26. Source
- Equity method fair value change added back: A change in fair value of equity method investments of $9,985 thousand is added back in the non-GAAP reconciliation, against $2,504 thousand in 2Q26. Source
Lucid EsoGuard reimbursement and volumes
- Medicare payments began in October: Lucid began receiving Medicare payments in October. Claims for its Texas laboratory go to Novitas, the MAC, and are paid at the established Clinical Laboratory Fee Schedule rate. Source
- Test volume and revenue in 3Q26: The company performed 2,871 EsoGuard tests and recognized $1.2 million of revenue in 3Q26, against 2,770 tests and $1.5 million of revenue in 2Q26. Source
- Real-world EsoGuard study published: The company announced publication of a real-world EsoGuard study of 11,991 patients in Diagnostics, described as the largest peer-reviewed study of nonendoscopic esophageal precancer testing to date. Source
“Veris continues to grow enrollment at Ohio State while advancing its implantable monitor toward FDA submission.”
Lishan Aklog, M.D., Chairman and Chief Executive Officer
Veris Health enrollment and device work
- OSU-The James enrollment nearly doubled: Monthly patient enrollment at OSU-The James rose through the quarter, nearly doubling from July to September, as the commercial phase of the engagement accelerated. Source
- Clinical rollout across most departments: The clinical rollout went live across most departments while the commercial phase of the strategic engagement continued to accelerate. Source
- Implantable monitor design freeze reached: Veris achieved design freeze for the implantable physiological monitor and began a 90-day GLP animal study in October. Source
PortIO and Octeris FDA engagement
- Initial FDA meeting on PortIO: The company held an initial meeting with FDA on PortIO in late October. Source
- Octeris probe ready for clinical testing: Octeris completed its next-generation multimodal endoscopic imaging probe, which is ready for clinical testing. Source
- FDA engagement on two devices: Management said the company is now actively engaged with FDA on both PortIO and Octeris. Source
“As Lucid’s largest common shareholder, PAVmed stands to benefit directly from Lucid’s substantial near-term revenue opportunity.”
Lishan Aklog, M.D., Chairman and Chief Executive Officer
Cash, capital and share count
- Cash balance rose to $8.9 million: Cash and equivalents, including restricted cash, were $8.9 million at September 30, 2026, up from $3.8 million at June 30, 2026. Restricted cash was $5.3 million. Source
- Non-GAAP share count increased: The non-GAAP share count for basic and diluted per-share figures was 6,640 thousand for 3Q26, up from 6,269 thousand in 2Q26 and 718 thousand in 3Q25. Source
- Preferred stock dividends in quarter: Preferred stock dividends and deemed dividends were $97 thousand for the quarter, against $945 thousand in 3Q25. Source
Strategy, positioning and subsidiaries
- Diversified medical technology positioning: The company describes itself as a diversified commercial-stage medical technology company in medical devices, diagnostics and digital health. Source
- Lucid largest common shareholder: Management said PAVmed is Lucid's largest common shareholder and stands to benefit directly from Lucid's near-term revenue following Medicare reimbursement. Source
- Veris described as digital health: Veris Health is described as a digital health company focused on personalized cancer care through remote patient monitoring with implantable sensors. Source
Coming up, as management said on 13 November 2026
- Octeris FDA package and study start: Octeris expects to submit its initial FDA pre-submission package this month. Enrollment in the University of North Carolina validation study is expected to begin in January 2027. Source
- PortIO in-person pre-submission meeting: An in-person pre-submission meeting on PortIO is to follow in January 2027, focused on the device's regulatory pathway. Source
Figures management reported
| Figure | Reported |
|---|---|
| EsoGuard tests performed, 3Q26 Source | 2,871 |
| EsoGuard tests, October 2026 Source | more than 1,800 |
Earlier plans management reported on
- Met: Management said design freeze for the implantable physiological monitor was achieved in the quarter. Source
Other quarters
Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.